Survival and invasiveness of astrocytomas promoted by erythropoietin

被引:33
作者
Mohyeldin, Ahmed
Dalgard, Clifton L.
Lu, Huasheng
Mcfate, Thomas
Tait, A. Sasha
Patel, Viral C.
Wong, Kondi
Rushing, Elizabeth
Roy, Subhojit
Acs, Geza
Verma, Ajay
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA
[2] Armed Forces Inst Pathol, Dept Neuropathol, Washington, DC 20306 USA
[3] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
hypoxia; glioma; erythropoietin; chemotherapy resistance;
D O I
10.3171/jns.2007.106.2.338
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Object. The hypoxia-inducible pleiotropic hormone, erythropoietin (EPO), has recently been found to promote the development and survival of neurons and astrocytes. Since hypoxia has been implicated in the malignant progression of some human cancers, the authors investigated whether EPO signaling influenced the malignant properties of human astrocytoma cells. Methods. Reverse transcriptase-polymerase chain reaction, Western blot analysis, and immunohistochemical studies were used to measure EPO and its receptor (EPOR). Cell viability, Matrigel invasion assays, metalloprotease assays, EPO neutralizing antibodies, and EPOR overexpression were used to study the biological actions of EPO. Expression of both EPO and EPOR was observed in the hypoxic regions and invasive margins of glioma specimens obtained at biopsy, and expression of EPOR correlated with the stage of the tumor. The EPOR was also functionally upregulated by hypoxia in cultured glioblastoma multiforme (GBM) cells. Both hypoxia and EPO protected cultured GBM cells from cisplatin cytotoxicity and promoted the invasiveness of GBM cells through Matrigel by potentiating metalloprotease activity. Hypoxia-enhanced cell invasion was attenuated in cells that overexpressed a nonfunctional EPOR. Conclusions. Hypoxia-inducible autocrine and paracrine EPO signaling participates in the malignant progression of GBMs.
引用
收藏
页码:338 / 350
页数:13
相关论文
共 73 条
[1]   Prognostic significance of erythropoietin expression in human endometrial carcinoma [J].
Acs, G ;
Xu, XW ;
Chu, C ;
Acs, P ;
Verma, A .
CANCER, 2004, 100 (11) :2376-2386
[2]   Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression [J].
Acs, G ;
Zhang, PJ ;
McGrath, CM ;
Acs, P ;
McBroom, J ;
Mohyeldin, A ;
Liu, SZ ;
Lu, HS ;
Verma, A .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (06) :1789-1806
[3]  
Acs G, 2001, CANCER RES, V61, P3561
[4]   Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway [J].
Akimoto, T ;
Kusano, E ;
Inaba, T ;
Iimura, O ;
Takahashi, H ;
Ikeda, H ;
Ito, C ;
Ando, Y ;
Ozawa, K ;
Asano, Y .
KIDNEY INTERNATIONAL, 2000, 58 (01) :269-282
[5]   ERYTHROPOIETIN HAS A MITOGENIC AND POSITIVE CHEMOTACTIC EFFECT ON ENDOTHELIAL-CELLS [J].
ANAGNOSTOU, A ;
LEE, ES ;
KESSIMIAN, N ;
LEVINSON, R ;
STEINER, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (15) :5978-5982
[6]   Expression of erythropoietin receptor splice variants in human cancer [J].
Arcasoy, MO ;
Jiang, XH ;
Haroon, ZA .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 307 (04) :999-1007
[7]   Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells [J].
Ashley, RA ;
Dubuque, SH ;
Dvorak, B ;
Woodward, SS ;
Williams, SK ;
Kling, PJ .
PEDIATRIC RESEARCH, 2002, 51 (04) :472-478
[8]  
ATKINS HL, 1991, BLOOD, V77, P2577
[9]   Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival [J].
Batra, S ;
Perelman, N ;
Luck, LR ;
Shimada, H ;
Malik, P .
LABORATORY INVESTIGATION, 2003, 83 (10) :1477-1487
[10]   Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells [J].
Beleslin-Cokic, BB ;
Cokic, VP ;
Yu, XB ;
Weksler, BB ;
Schechter, AN ;
Noguchi, CT .
BLOOD, 2004, 104 (07) :2073-2080